MATERIAL SAFETY DATA SHEET
Section I - IDENTITY
Doxycycline for Injection, USPChemical Names:
Vibramycin Intravenous, Doxycycline, Liviatin, Doxiciclina, GS-3056 Manufacturer's Name:
Emergency Telephone Number:
Telephone Number for Info.:
(440)232-3320 -or- (800)562-4797Medical Emergency:
Professional Services 1(800)521-5169Date Prepared:
- HAZARDOUS INGREDIENTS/COMPOSITION INFORMATION
OSHA PEL ACGIH TLV
Doxycycline is a sterile lyophilized drug provided in a vial.
- HEALTH HAZARD DATA
Routes of Entry:
Under normal use, Doxycycline presents little hazard. It may be
absorbed through the skin, through ingestion or via inhalation of aerosols.
Health Hazard (Acute & Chronic):
Doxycycline is a broad spectrum antibiotic used to treat a variety of
gram positive and gram negative organisms. It may affect the digestive system and may cause allergic reactions.
NO IARC Monographs?
Signs & Symptoms of Exposure:
Doxycycline may cause irritation to the eyes, skin and respiratory
tract. It may also cause nausea, vomiting diarrhea, and difficulty in swallowing. May cause allergic
Medical Conditions Generally Aggravated by Exposure:
Persons who are allergic to tetracyclines.BVL Hazard Category:
- FIRST AID MEASURES
Flush eyes with large volumes of water for 15 or more minutes.Skin Exposure:
Wash skin with cool, soapy water for 15 minutes.Ingestion:
If ingestion occurs, flush mouth with water and seek medical attention immediately.
If person is conscious, induce vomiting. Never induce vomiting on an unconscious person.
If difficulty breathing, administer oxygen. Seek attention of a physician immediately.
If necessary, provide artificial respiration.
- FIRE AND EXPLOSION HAZARD DATA
Flash Point (Method Used):
Not Applicable LEL:
Not Applicable UEL:
Not ApplicableFlammable Limits:
Not ApplicableExtinguishing Media:
Use water or an ABC multi-purpose extinguisher.Special Fire Fighting Procedures:
As with all fires, evacuate personnel to a safe area. Fire fighters
should wear self-contained breathing apparatus to avoid inhalation of smoke.
Unusual Fire/Explosion Hazards:
- ACCIDENTAL RELEASE INFORMATION
Release to Land:
Wet and wipe up Doxycycline with absorbent materials and dispose according to local,
Release to Air:
If aerosolized, reduce exposures by ventilating area; clean up spill immediately to
Release to Water:
Refer to local water authority. Drain disposal is not recommended; however,
refer to local, state, and federal disposal guidelines.
- PRECAUTIONS FOR SAFE HANDLING AND USE
Steps to be taken in case material is released or spilled:
See Section VI above.
Wear latex or nitrile gloves and safety glasses when cleaning spills. A dust/mist respirator (N95)may be necessary if excessive aerosols are generated.
Waste Disposal Method:
Incineration in an approved incinerator is recommended. Refer to local, state,
Precautions to be taken in handling and storing:
Store at 25º C (77ºF). Follow instructions
provided in packaging. Protect from light.
- CONTROL MEASURES AND PERSONAL PROTECTIVE EQUIPMENT
Under normal use, respirators are not required. If aerosols are generated, a
disposable dust/mist respirator (N95) may be used. Personnel wearing respirators should be fittested and approved for respirator use under the OSHA Respiratory Protection Standard 29 CFR1910.134.
Handle product in a well-ventilated area.Protective Gloves:
Latex or nitrile
Other Protective Clothing or Equipment:
Wash hands following use. No eating, drinking, or smoking while
- PHYSICAL/CHEMICAL CHARACTERISTICS
Appearance and Odor:
Solubility in Water:
- STABILITY AND REACTIVITY DATA
Stable Incompatibility (Materials to Avoid):
Strong oxidizers or water-reactive materials.Hazardous Decomposition or Byproducts:
Decomposition products of this compound may include
potentially hazardous byproducts of nitrogen oxides, carbon monoxide, carbon dioxide, andsulfur oxides.
Will not occurConditions to Avoid:
Storage near oxidizers and water reactive materials
- TOXICOLOGICAL INFORMATION
LD50 mouse, intravenous = 241 mg/kgLD50 mouse, oral = 1870 mg/kgLD50 rat, intraperitoneal = 378 mg/kgLD50 rat, intravenous = 228 mg/kgLD50 rat, oral = >2 g/kgLD50 mouse, intraperitoneal = 410 mg/kg LD50 dog, intravenous = >100 mg/kgLD50 dog, oral = >500 mg/kg
Additional reproductive health data is available from the National Institute for Occupational Safety andHealth (NIOSH) Registry of Toxic Effects of Chemical Substances (RTECS).
- ENVIRONMENTAL IMPACT INFORMATION
Information is currently not available on the environmental impact of Doxycycline. Handle in a manner toprevent spills or releases to the environment.
- DISPOSAL INFORMATION
Dispose of by incineration at an approved/permitted incinerator.
Review local, state, and federal regulations for your regulatory area.
- TRANSPORTATION INFORMATION
Doxycycline is not a DOT hazardous material.
Doxycycline is not a DOT Marine Pollutant.
- REGULATORY INFORMATION
Doxycycline is listed on California’s Proposition 65 List as Code D
- OTHER DATA
Use of this product should be through or under the direction of a physician.
This MSDS does not address therapeutic use of this material.
Persons administering this drug to patients must be careful to avoid needle sticks to syringes and other sharps used in the administration. All needle sticks must be reported to your companymanagement.
The information provided is believed to be complete and accurate. It is the user's responsibility to use the information according to theirapplication. Bedford Laboratories and Ben Venue Labs, Inc. assumes no additional liability or responsibility resulting from the use of orreliance on this information.
Riccardo Primo, Re D’Inghilterra Libretto di Paolo Antonio Rolli, adattato da "ISACIO TIRANNO" di Francesco Briani Londra, 11 novembre 1727 Musica di George Frederich H andel Personaggi: Riccardo Primo, Re d'Inghilterra Costanza, principessa di Navarra, sua promessa sposa Berardo, cugino e tutore di Costanza Isacio, tiranno di Cipro P
Lucidoc Form #36332, revision 0, 2/10/2010 Also found at http://www.pph.org/media/file/Pharmacy/PreopMeds(2).pdf See also Lucidoc Procedure #15076 – “Preoperative Patient Screening for Pre-Admission” for details on how this form will be used. Adapted from UpToDate.com topic on “Perioperative Medication Management”1 and other sources2,3,4,5,6 MEDICATION CLINICAL CONCERN DAY B